Top Industry Leaders in the Gastrointestinal Drugs Market
Latest Gastrointestinal Drugs Companies Update:
Takeda Pharmaceutical Company Limited Received FDA approval for Entyvio® (vedolizumab) for the treatment of ulcerative colitis in pediatric patients aged 6 years and above, expanding their market reach and patient access. Partnered with research institutions to develop next-generation therapies for IBD and other GI conditions.
AbbVie Launched Humira® (adalimumab) biosimilar for the treatment of various GI disorders, offering a more affordable alternative for patients and healthcare systems. Focused on expanding their portfolio of biosimilars and biologics for chronic disease management.
Johnson & Johnson Announced the Phase 3 development program for Stelara® (ustekinumab) for the treatment of eosinophilic esophagitis, aiming to address a high unmet need in this patient population. Collaborated with patient advocacy groups to raise awareness and improve diagnosis of rare GI diseases.
Pfizer Launched Xeljanz® (tofacitinib) for the treatment of moderate-to-severe ulcerative colitis, offering a new oral medication option for managing this chronic condition. Focused on developing innovative small molecule drugs for diverse GI disorders.
AstraZeneca Partnered with Roivant Sciences to commercialize RVT-3101, a novel oral therapy for ulcerative colitis, expanding their pipeline and market presence in IBD treatment. Invested in research and development of precision medicine approaches for personalized GI care.
List of Gastrointestinal Drugs companies in the market
- Takeda Pharmaceuticals
- Allergan Plc
- Novo Nordisk A/S
- AstraZeneca Plc
- AbbVie Inc.
- Valeant Pharmaceuticals Inc.
- Johnson & Johnson
- Bayer AG
- Boehringer Ingelheim GmbH
- GlaxoSmithKline Plc.
- Janssen Biotech Inc.
- Sanofi